# Spago Nanomedical > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/spagonanomedical). ## Overview Spago Nanomedical is a Swedish clinical-stage life science company developing nanomedicine-based products for cancer treatment and imaging diagnostics. Its core programs are Tumorad, a radionuclide therapy platform, and SpagoPix, a contrast agent platform for MRI-based imaging, both built on patented functional nanoparticles designed to accumulate in tumors. ## Products & services • Tumorad® radionuclide therapy program • 177Lu-SN201 candidate for aggressive cancer • SpagoPix imaging contrast agent program • Nanoparticle platform for tumor-targeting diagnostics and therapy - **Radionuclide therapy development** (50%) — Development of Tumorad and the 177Lu-SN201 candidate for cancer treatment. - **Imaging diagnostics development** (35%) — SpagoPix contrast-agent development for improved MRI precision in cancer and endometriosis. - **Nanoparticle platform technology** (15%) — Patented functional nanoparticle platform used across therapeutic and diagnostic programs. - Tumorad® radionuclide therapy program - 177Lu-SN201 candidate for aggressive cancer - SpagoPix imaging contrast agent program - Nanoparticle platform for tumor-targeting diagnostics and therapy ## Customers Spago Nanomedical does not sell to a broad commercial customer base today; its primary counterparties are pharmaceutical and biotech partners, clinical investigators, and potential licensees. The end users of its products are patients with cancer and other severe diseases, while future commercialization is intended to occur through out-licensing or strategic partnerships with larger drug companies. - **Pharmaceutical license partners** (primary) — Buy or license late-stage development rights and commercialize the programs after proof of concept. - **Clinical trial participants and sites** (primary) — Provide patient enrollment and clinical execution for Tumorad and related studies. - **Biotech and research collaborators** (secondary) — Support development, validation, and translational work around the nanoparticle platform. - **Healthcare end users** (secondary) — Patients and clinicians ultimately use the therapy and imaging products once commercialized. - Pharmaceutical partners seeking licensed oncology assets - Biotech collaborators supporting clinical development - Clinical trial sites enrolling advanced-cancer patients - Future commercial partners with global development capacity - Patients with cancer and other severe diseases as end users ## Geography The company is headquartered in Lund, Sweden and operates as a Swedish listed clinical-stage developer on Nasdaq First North Growth Market. Its current work is centered in Sweden, while future value creation depends on global pharmaceutical partners and eventual international commercialization of its oncology programs. - **Sweden** (100%) — Corporate headquarters and current operations are based in Lund. - Headquartered in Lund, Sweden - Listed on Nasdaq First North Growth Market - Clinical development and corporate functions are Sweden-based - Future commercialization is intended to be international - Partnering model reduces dependence on a single geography ## Strategy Spago Nanomedical’s strategy is to advance its nanoparticle-based programs through clinical proof of concept under its own control, then out-license or partner with established pharmaceutical companies. This model is designed to concentrate internal resources on high-value development milestones while relying on partners for broad commercialization and market access. - **Clinical proof of concept for Tumorad** (short-term) — Clinical validation is the key value-inflection point for a radiopharmaceutical asset. - **Advance SpagoPix imaging diagnostics** (medium-term) — A second program broadens the platform and creates another partnering opportunity. - **Secure strategic licensing or partnership agreements** (medium-term) — Commercial partners provide development capacity, regulatory reach, and market access. - Advance Tumorad through clinical proof of concept - Develop SpagoPix as an imaging-diagnostics platform - Use partnerships for later-stage development and commercialization - Leverage patented nanoparticle technology across programs - Target diseases with high unmet medical need ## Risks The business is exposed to the typical risks of clinical-stage drug development: technical failure, trial delays, patent protection, and uncertainty around regulatory and commercial outcomes. Financing risk is also central because the company depends on external capital and/or partnering success before product revenues can be generated. - **Clinical development risk** [high] — The company must demonstrate safety, biodistribution, and efficacy in human studies before partnering value is realized. - **Financing risk** [high] — The company is pre-commercial and depends on external funding to sustain R&D and trials. - **Intellectual property risk** [medium] — The platform depends on patents and other rights to protect future licensing value. - **Partnering and commercialization risk** [medium] — Future revenues depend on finding capable licensees or collaborators with global reach. - Clinical trial failure or delays can reduce program value - Patent and IP disputes could weaken exclusivity - Financing needs are high before commercialization - Partnering risk affects future monetization timing - Regulatory and development uncertainty is inherent in oncology ## Accounting Spago Nanomedical reports under Swedish K3 rules, which is typical for a small clinical-stage company but still leaves judgment-heavy areas around grants, capitalization, and impairment. Because the company has limited operating revenue, accounting outcomes are sensitive to how public grants, financial assets, and development-related costs are recognized and measured. - **Public grants** — Affects reported revenue/other income timing - **Deferred tax assets** — Loss carryforwards may not appear as balance-sheet value - **Financial asset impairment** — Can create volatility in financial items - Public grants may be recognized as revenue or other income - No deferred tax assets are recognized without probable future profits - Impairment of financial assets affects reported results - K3 reporting can differ from IFRS in presentation and measurement - Clinical-stage spending is expensed unless capitalization criteria are met --- *Last updated: 2026-08-11T04:04:55.893977+00:00*